Medindia

X

Tests for New Alzheimer Drug Halted by Pfizer and Johnson & Johnson

by Kathy Jones on  August 7, 2012 at 7:35 PM Clinical Trials News   - G J E 4
Tests for a new therapy to treat Alzheimer's disease have been halted by Pfizer and Johnson & Johnson as the new drug failed to meet expectations.
 Tests for New Alzheimer Drug Halted by Pfizer and Johnson & Johnson
Tests for New Alzheimer Drug Halted by Pfizer and Johnson & Johnson
Advertisement

The final, phase 3 trial of the intravenous bapineuzumab therapy did not meet targets for effectiveness in aiding cognitive and functional performance of Alzheimer's victims, according to the two drug giants.

Advertisement
As a result, they decided to end the program to develop the treatment, they said.

"We are obviously very disappointed in the outcomes of this trial. We are also saddened by the lost opportunity to provide a meaningful advance for patients afflicted with mild-to-moderate Alzheimer's disease and their caregivers," said Steven Romano, senior vice president at Pfizer Inc.

"Yet these data, and the subgroup and biomarker analyses under way, will further inform our understanding of this complex disease and advance research in this field."

Source: AFP
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All